Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan to Overhaul Diabetes Trial Guidelines to Align with Global Standards and Prevent Drug Lag/Loss
July 7, 2025
- Healthcare-Linked Candidates Launch Campaigns as Upper House Election Gets Underway
July 4, 2025
- Upper House Campaign Begins in Japan, Healthcare and Pharma-Linked Candidates in Spotlight
July 3, 2025
- Ex-Health Minister Takemi Vows to Bolster Japan’s Drug Development and Supply Resilience
July 2, 2025
- MHLW Shuffles Senior Bureaucrats, Miyamoto to Head Pharma Safety Bureau
July 2, 2025
- LDP’s Honda Pledges Strong Support for Pharma Sector via Pro-Innovation Pricing and Supply Stabilization
July 2, 2025
- Japan Publishes 2025 Strategy Report on Clinical Trials, Backs Single IRB as General Rule
July 1, 2025
- Average Annual Pay for PMDA Staffers at 7.99 Million Yen in FY2024
July 1, 2025
- LDP’s Furukawa Vows Policy Support for Domestic Innovation in New Modalities
June 30, 2025
- MOF Poised to Discuss Use of CEA System with MHLW: Budget Examiner
June 30, 2025
- Japan Hands Out Orphan Tags to Ultragenyx’s Setrusumab and Lots More
June 30, 2025
- Japan Launches Public-Private Council to Create Innovation Ecosystem
June 27, 2025
- DPP’s Tamura Renews Call to Scrap Off-Year Drug Price Cuts, Urges Protection of On-Patent Prices
June 26, 2025
- Japan Begins FY2026 Drug Pricing Reform Talks; Responses to Inflation, High-Cost Therapies on Agenda
June 26, 2025
- Chuikyo OKs Drug Price Survey Plan for FY2026 Revision
June 26, 2025
- Study Group Urges Japan to Accelerate Genomic Medicine Rollout
June 26, 2025
- MHLW Orders Label Revisions for Desmopressin, Thiamazole
June 25, 2025
- Japan Approves MSD’s Airwin/Welireg, J&J Bispecific, and More
June 25, 2025
- JPWA Poll Finds Progress in Unit Price-Based Negotiations, but Frequent and Lengthy Bargaining Persists
June 25, 2025
- Japan Sets June 26 for First Meeting of Public-Private Council for Biopharmaceutical Innovation
June 24, 2025
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…